stockrow
Saturday 7 November 2026
Export SILO’s income statement to Excel — free account
Silo Pharma, Inc.
SILO Healthcare Biotechnology
Silo Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72,100.00, roughly unchanged from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +73.3%
- Free cash flow
- +39.2%
Quarter to June 2026, against a year earlier
1.33
0.04
+3.10%
Follow SILO
Alert me
Silo Pharma, Inc. (SILO) P/E ratio
Silo Pharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 7.0× (April 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 3.5× | — |
| FY2019 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 21 more quarters | Free account |
Against its own ten years
Low 0.0×
High 7.0×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EDVA Splash Beverage Group, Inc. compare | n/m |
| BRTX Biorestorative Therapies, Inc. compare | n/m |
| SILO Silo Pharma, Inc. | n/m |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| HCWB HCW Biologics Inc. compare | n/m |
| APVO Aptevo Therapeutics Inc. compare | n/m |
| SLXN Silexion Therapeutics Corp compare | n/m |
| ENLV Enlivex Ltd. compare | 0.0× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)